

VcMMAE

Catalog No: tcsc1242



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

646502-53-6

Formula:

$C_{68}H_{105}N_{11}O_{15}$

Pathway:

Cell Cycle/DNA Damage;Cytoskeleton;Antibody-drug Conjugate/ADC Related

Target:

Microtubule/Tubulin;Microtubule/Tubulin;Drug-Linker Conjugates for ADC

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 54 mg/mL (41.01 mM)

Alternative Names:

mc-vc-PAB-MMAE


Observed Molecular Weight:
1316.63

Product Description

VcMMAE is a **drug-linker conjugate for ADC** with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).

In Vitro: Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30⁺ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells^[1]. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells^[2].

In Vivo: Monomethyl auristatin E (MMAE) in combination with IR results in tumor growth delay, tumor-targeted ACPD-cRGD-MMAE with IR produces a more robust and significantly prolonged tumor regression in xenograft models^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!